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opportune time to review progress in global TB
control. The World Health Organization’s (WHO)
Global TB Report 2014, published in October
2014, estimated that 9 million people developed
TB in 2013, and 1.5 million died [1]. These figures
are higher (half a million more cases) than what
was estimated for the previous year, presumably
because of intensive efforts to improve data
collection and reporting.
Three issues in the latest WHO report are worri-
some and worth highlighting. First is the enormous
number of lives that are lost because of TB, which,
for most part, is a highly curable disease. It is
incredible that TB continues to be the second big-
gest killer disease from a single infectious agent.
The second fact is the estimate by WHO that nearly
3 million people with TB are still being ‘missed’ by
healthcare systems every year, either because they
are undiagnosed, or because they are diagnosed
but not notified to the healthcare system. The third
issue is the continuing burden of multidrug-resis-
tant TB (MDR-TB) with an estimated 480,000 new
cases in 2013. Increasing use of rapid molecular
tests like Xpert MTB/RIF (Cepheid Inc, Sunnyvale,
CA) has resulted in a tripling of MDR-TB cases being
diagnosed [1]. With nearly 9 million Xpert MTB/RIF
tests procured (by last quarter of 2014), it is highly
likely that we will uncover more and more cases of
MDR-TB [2].
Missing cases, high death rate, and drug-resis-
tance all point to one critical underlying problem
– that high burden countries are unable to guaran-
tee an acceptable quality of TB care to all patients,
regardless of whether they seek care in the publicor the private sector [3,4]. If patients with classic
TB symptoms are not being diagnosed, this suggests
poor adherence to international standards for
diagnosis [5]. If patients are developing MDR-TB,
this suggests poor adherence to treatment stan-
dards, and suboptimal adherence monitoring [5].
If patients with TB are not being notified, this
suggests lack of engagement of private and infor-
mal health sector providers who often see TB
patients first.
WHO, the Stop TB Partnership, and key stake-
holders are aware of these serious challenges,
and have recently announced an ambitious End TB
Strategy, which aims to end the global TB epi-
demic, with targets to reduce TB deaths by 95%
and to cut new cases by 90% between 2015 and
2035, and to ensure that no family is burdened with
catastrophic expenses due to TB [6]. A strategy to
end TB is very ambitious and definitely welcome,
because it may inspire country governments to step
up their level of ambition and invest more in TB
control. Indeed, the Indian government recently
announced an ambitious plan to eliminate TB by
2020, and has endorsed the goal of universal access
to quality TB diagnosis and treatment for all
patients [7].
The critical importance of ambition, activism
and advocacy is easily illustrated by the successes
in the area of HIV prevention and care. A similar
level of ambition and advocacy for TB control is
great to see. However, if countries do not put
resources behind ambitious plans, then progress
will be stymied. India’s expenditure on TB control,
for example, continues to be low, and TB elimina-
tion by 2020 is inconceivable at the current level of
2 Editorialinvestment [7]. In contrast to China which made
major investments in TB control and successfully
reduced the prevalence of TB by more than half
in the past 10 years [8], India has a long way to
go in scaling up its capacity to detect and treat
MDR-TB, engage the massive private sector,
improve quality of care in the private sector, and
address critical social determinants such as malnu-
trition and poverty. All of these will require sub-
stantially higher budgets than what is currently
available [7,9].
Globally, the funding gap in TB has been high-
lighted [1]. An estimated US$ 8 billion is needed
each year for a full response to the global epi-
demic, but there is currently an annual shortfall
of US$ 2 billion [1]. Similar gaps in TB research
and development (R&D) expenditure have also
been highlighted [10]. Without sustained invest-
ments in R&D, it is unlikely that we will have new
tools such as new TB drug regimens and vaccines.
The Stop TB Partnership’s theme for World TB
Day 2015 is ‘‘Reach, Treat, Cure Everyone.’’ With-
out adequate resources, no country can reach and
cure everyone. Political leaders and policy makers
need to understand that TB cannot be eliminated
without investing more resources. However, in
the long run, TB control will result in substantial
cost savings, and bring significant economic and
health benefits to any country.
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